Financial Performance - The company reported a total revenue of 5.379 billion yuan for the first half of 2025, a decrease of 4.81% year-on-year [1] - The net profit attributable to shareholders was 1.442 billion yuan, down 16.22% compared to the previous year [1] - The gross profit margin was 40.41%, reflecting a decline of 9.68% year-on-year, while the net profit margin decreased by 12.99% to 26.92% [1] Quarterly Analysis - In Q2 2025, the total revenue was 2.237 billion yuan, a decline of 9.79% year-on-year [1] - The net profit for Q2 2025 was 443 million yuan, showing a significant drop of 40.76% compared to the same quarter last year [1] Cost and Expenses - Total selling, administrative, and financial expenses amounted to 381 million yuan, which accounted for 7.08% of revenue, an increase of 3.89% year-on-year [1] - The company's cash flow per share was 0.62 yuan, a decrease of 1.56% year-on-year [1] Investment Metrics - The company's return on invested capital (ROIC) was 19.28% last year, indicating strong capital returns [3] - The average expected earnings per share for 2025 is projected to be 5.19 yuan, with an anticipated total profit of 3.132 billion yuan [3] Fund Holdings - The largest fund holding shares of the company is the E Fund CSI 300 Medicine ETF, which has reduced its holdings [4] - The fund's current scale is 20.601 billion yuan, with a recent net value increase of 2.74% [4]